Enduring neurological sequelae of benzodiazepine use: an Internet survey.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Psychopharmacology Pub Date : 2023-02-06 eCollection Date: 2023-01-01 DOI:10.1177/20451253221145561
Christy Huff, A J Reid Finlayson, D E Foster, Peter R Martin
{"title":"Enduring neurological sequelae of benzodiazepine use: an Internet survey.","authors":"Christy Huff, A J Reid Finlayson, D E Foster, Peter R Martin","doi":"10.1177/20451253221145561","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated.</p><p><strong>Objective: </strong>This secondary analysis of the results from an Internet survey sought to better understand the acute and protracted withdrawal symptoms associated with benzodiazepine use and discontinuation.</p><p><strong>Methods: </strong>An online survey (<i>n</i> = 1207) was used to gather information about benzodiazepine use, including withdrawal syndrome and protracted symptoms.</p><p><strong>Results: </strong>The mean number of withdrawal symptoms reported by a respondent in this survey was 15 out of 23 symptoms. Six percent of respondents reported having all 23 listed symptoms. A cluster of least-frequently reported symptoms (whole-body trembling, hallucinations, seizures) were also the symptoms most frequently reported as lasting only days or weeks, that is, short-duration symptoms. Symptoms of nervousness/anxiety/fear, sleep disturbances, low energy, and difficulty focusing/distractedness were experienced by the majority of respondents (⩾85%) and, along with memory loss, were the symptoms of longest duration. Prolonged symptoms of anxiety and insomnia occurred in many who have discontinued benzodiazepines, including over 50% who were not originally prescribed benzodiazepines for that indication. It remains unclear if these symptoms might be caused by neuroadaptive and/or neurotoxic changes induced by benzodiazepine exposure. In this way, benzodiazepine withdrawal may have acute and long-term symptoms attributable to different underlying mechanisms, which is the case with alcohol withdrawal.</p><p><strong>Conclusions: </strong>These findings tentatively support the notion that symptoms which are acute but transient during benzodiazepine tapering and discontinuation may be distinct in their nature and duration from the enduring symptoms experienced by many benzodiazepine users.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/01/10.1177_20451253221145561.PMC9905027.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253221145561","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic underpinnings of enduring symptoms that can last months or years have not yet been elucidated.

Objective: This secondary analysis of the results from an Internet survey sought to better understand the acute and protracted withdrawal symptoms associated with benzodiazepine use and discontinuation.

Methods: An online survey (n = 1207) was used to gather information about benzodiazepine use, including withdrawal syndrome and protracted symptoms.

Results: The mean number of withdrawal symptoms reported by a respondent in this survey was 15 out of 23 symptoms. Six percent of respondents reported having all 23 listed symptoms. A cluster of least-frequently reported symptoms (whole-body trembling, hallucinations, seizures) were also the symptoms most frequently reported as lasting only days or weeks, that is, short-duration symptoms. Symptoms of nervousness/anxiety/fear, sleep disturbances, low energy, and difficulty focusing/distractedness were experienced by the majority of respondents (⩾85%) and, along with memory loss, were the symptoms of longest duration. Prolonged symptoms of anxiety and insomnia occurred in many who have discontinued benzodiazepines, including over 50% who were not originally prescribed benzodiazepines for that indication. It remains unclear if these symptoms might be caused by neuroadaptive and/or neurotoxic changes induced by benzodiazepine exposure. In this way, benzodiazepine withdrawal may have acute and long-term symptoms attributable to different underlying mechanisms, which is the case with alcohol withdrawal.

Conclusions: These findings tentatively support the notion that symptoms which are acute but transient during benzodiazepine tapering and discontinuation may be distinct in their nature and duration from the enduring symptoms experienced by many benzodiazepine users.

Abstract Image

Abstract Image

Abstract Image

使用苯并二氮杂卓引起的持久性神经系统后遗症:一项互联网调查。
简介:苯二氮卓类药物的减量和停用与持续时间长短不一的各种症状组合有关。虽然几十年前就有文献描述过,但持续数月或数年的持久症状的机理基础尚未阐明:这项对互联网调查结果的二次分析旨在更好地了解与使用和停用苯并二氮杂卓相关的急性和长期戒断症状:方法:通过在线调查(n = 1207)收集有关苯二氮卓使用的信息,包括戒断综合征和长期症状:在这项调查中,受访者报告的戒断症状的平均数量为 23 种症状中的 15 种。6%的受访者报告了所有 23 种症状。最不经常报告的一组症状(全身颤抖、幻觉、癫痫发作)也是最经常报告的仅持续数天或数周的症状,即短时症状。大多数受访者(⩾85%)都有紧张/焦虑/恐惧、睡眠障碍、精力不足和注意力难以集中/分散的症状,这些症状与记忆力减退一起,是持续时间最长的症状。许多停用苯二氮卓类药物的受访者都出现了长时间的焦虑和失眠症状,其中超过 50%的受访者最初并没有服用苯二氮卓类药物。目前还不清楚这些症状是否可能是由于接触苯二氮卓引起的神经适应性和/或神经毒性变化所致。因此,苯二氮卓类药物戒断可能会出现急性和长期症状,其根本机制不同,酒精戒断也是如此:这些研究结果初步支持这样一种观点,即在苯二氮卓类药物减量和停药期间出现的急性但短暂的症状,在性质和持续时间上可能与许多苯二氮卓类药物使用者经历的持久症状不同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信